Table 1.
Summary of cases of COVID-19-vaccine-associated MEWDS.
| Authors | Age | Sex | Race | Vaccine | Dose | Time from Vaccine to Symptoms (Days) | Ocular Symptoms | Past History | Course | Initial VA | Final VA | Treatment | Resolution |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bolletta et al. [26] | 53 | M | _ | Pfizer BNT162b2 | 2nd | 28 | Decreased VA, scotoma, | None | Acute | 20/25 | 20/20 | Observation | Complete resolution |
| 18 | F | _ | Pfizer BNT162b2 | 1st | 4 | Blurred vision, visual field defect | None | Acute | 20/66 | 20/20 | Observation | Complete resolution | |
| 48 | M | _ | Pfizer BNT162b2 | 1st | 7 | Decreased VA | None | Acute | 20/400 | 20/20 | Observation | Complete resolution | |
| Xu et al. [13] | 49 | F | _ | Sinovac- CoronaVAC vaccine (Inactivated) |
1st | 2 | Blurred vision | MEWDS | Recurrent | 20/100 | 20/20 | Tapered prednisone, starting with 20 mg | Complete resolution |
| Lin et al. [27] | 36 | F | Taiwanese | Medigen Vaccine Biologics Corporation (MVC) COVID-19 Vaccine | 1st | 2 | Photopsia | High myopia (−9.75D/−7.5D) | Acute | 20/25 | 20/20 | observation | Complete resolution in 4 weeks |
| Smith et al. [28] | 15 | M | _ | Pfizer BNT162b2 | 2nd | 14 | Blurred vision, myodesopsia, photopsia | None | Acute | 20/100 | 20/20 | Tapered oral prednisone, starting at 40 mg | Complete resolution in 2 weeks |
| 21 | F | _ | Pfizer BNT162b2 | 2nd | 21 | Blurred vision | None | Acute | 20/60 | 20/20 | Tapered oral prednisone, starting at 40 mg | Complete resolution in 2 weeks | |
| Yasuda et al. [29] | 67 | F | Japanese | Pfizer BNT162b2 | 2nd | 1 | Scotoma, photopsia, blurred vision | None | Acute | 20/100 | 20/25 | _ | Patient also developed moderate vitritis, almost complete resolution at 2 weeks. |
| Inagawa et al. [30] | 30 | F | Japanese | Pfizer BNT162b2 | 1st, 2nd | 7 and 3, respectively | Blurred vision | None | Recurrent | 20/20 OU | 20/30 | Topical 0.1% fluorometholone for 21 days | Both eyes had fundus abnormalities L>R |
| Tomishige et al. [31] | 38 | F | White | Sinovac- CoronaVac vaccine (Inactivated) |
1st | 7 | Photopsia, decreased VA | None | Acute | 20/400 | 20/20 | Tapered oral prednisone, starting at 80 mg oral prednisone | Complete resolution in 4 weeks |
| Rabinovitch et al. [32] | 28 | F | _ | Pfizer BNT162b2 | 2nd | 0 | Blurred vision, scotoma, photopsia | None | Acute | _ | _ | _ | Significant improvement on FU |
| 39 | M | _ | Pfizer BNT162b2 | 2nd | _ | Blurred vision, scotoma, photopsia | None | Acute | _ | _ | _ | Significant improvement on FU | |
| Alhabshan et al. [33] | 71 | F | White | Moderna mRNA-1273 | 1st booster | 3 | Blurred vision and scotoma | Myopic and retinal tear | Acute | 20/30 | _ | _ | Spontaneous improvement |